Key result
Ultra-short term DAPT (≤1 month) followed by P2Y12 monotherapy has a superior safety profile compared to 12-month DAPT in patients with acute coronary syndrome.
Why the study?
The overall safety profile of ultra-short term (≤1 month) DAPT followed by P2Y12 monotherapy compared to long term (12 months) DAPT after PCI in ACS remains uncertain.
Does ultra-short term (≤1 month) DAPT followed by P2Y12 monotherapy improve the overall safety profile compared to long term (12 months) DAPT in patients with ACS following PCI?
Does ultra-short term (≤1 month) DAPT followed by P2Y12 monotherapy improve the overall safety profile compared to long term (12 months) DAPT in patients with ACS following PCI?
Answers are grounded in this paper and cite their sources.
Ultra-short term DAPT (≤1 month) followed by P2Y12 monotherapy appears to offer a superior safety profile compared to standard 12-month DAPT in ACS patients undergoing PCI.
Short term dual antiplatelet therapy (DAPT) may reduce bleeding risk following percutaneous intervention (PCI) in acute coronary syndrome (ACS) but the overall safety profile of ultra-short term (≤1 month) DAPT followed by P2Y12 monotherapy compared to long term (12 months) DAPT remains uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to bridge evidence gap.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question. Ultra-short term DAPT (≤1 month) followed by P2Y12 monotherapy has a superior safety profile compared to 12-month DAPT in patients with acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: